The abstract is read at the publisher; the summary is JClub's.
ASTRUM-006 shows that perioperative immune checkpoint inhibition improves event-free survival by phase 3 evidence when combined with Asian SOX-based chemotherapy in PD-L1-positive gastric cancer.
- Why it matters: Perioperative options for PD-L1-positive gastric cancer need stronger outcomes than chemotherapy alone, and immune checkpoint timing and intensity remain key uncertainties.
- What they did: In a phase 3 setting, investigators tested perioperative immune checkpoint inhibition alongside Asian SOX-based chemotherapy, using event-free survival as the primary outcome.
- The result: The results support a chemotherapy-sparing postoperative strategy and expand perioperative treatment options, while highlighting the need to consider event adjudication and metastatic status.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.